Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kogo (Kobe, Japan), Y. Satsuma (Kobe, Japan), K. Kusuda (Kobe, Japan), H. Ikesue (Kobe, Japan), R. Mori (Kobe, Japan), D. Fujimoto (Kobe, Japan), K. Nagata (Kobe, Japan), A. Nakagawa (Kobe, Japan), R. Tachikawa (Kobe, Japan), K. Otsuka (Kobe, Japan), K. Tomii (Kobe, Japan). Team support with pharmacists improved tolerability of antifibrotic agents for pulmonary fibrosis.. 4783

Member's Comments

No comment yet.

Related content which might interest you: Tolerability and safety of anti-fibrotic agents for idiopathic pulmonary fibrosis in real world Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Impact of compliance and specialist nurse support on IPF survival in patients commenced on antifibrotic therapy Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018 Year: 2018 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Factors affecting the compliance to antifibrotic treatment in patients with interstitial pulmonary fibrosis Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 A prosprective study on the safety, tolerability and efficacy of pirfinidone in the treatment of idiopathic pulmonary fibrosis and fibrotic NSIP Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis Year: 2012 Adherence to anti-fibrotic therapy in IPF; the nurses’ challenge Source: International Congress 2017 – Delivering person-centred care across the spectrum of respiratory nursing Year: 2017 Healthcare resource use and related costs in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Management of chronic lung conditions Year: 2020 Efficacy of switching antifibrotic therapy in idiopathic pulmonary fibrosis: real life data Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Safety of antifibrotic drugs in idiopathic pulmonary fibrosis patients awaiting lung transplantation Source: International Congress 2018 – Moving lung transplantation forward Year: 2018 The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Results of antifibrotic drugs in the treatment of idiopathic pulmonary fibrosis. A real life study. Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA Source: Eur Respir J, 52 (1) 1702106; 10.1183/13993003.02106-2017 Year: 2018 Long-term tolerability of real-life use of antifibrotic agents (AFA) in Idiopathic Pulmonary Fibrosis (IPF) Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients? Source: Eur Respir Rev 2011; 20: 201-207 Year: 2011